A Pharmacokinetics Study of Aleglitazar in Combination With Digoxin in Healthy Volunteers

Inclusion Criteria: * Healthy volunteers, 18-55 years of age, inclusive * Body mass index (BMI) between 18.0 and 30.0 kg/m2 inclusive. * Females must be either surgically sterile or post-menopausal for at least one year or, if they are of child-bearing potential, must use two acceptable methods of contracepetion * Volunteer normally drinks no more than three cups of coffee/tea/caffeinated soft drinks per day and is willing to stop drinking coffee/tea/caffeinated soft drinks during the study Exclusion Criteria: * Any clinically relevant abnormal laboratory test results at screening or on Day -1 * Has taken any prescribed or herbal/over the counter medication within 2 weeks prior to the first dosing * A history of clinically significant gastro-intestinal, cardiovascular, musculoskeletal, endocrine, hematological, psychiatric, renal, hepatic, bronchopulmonary or neurological conditions or lipid metabolism disorders. * Infection with human immunodeficiency virus (HIV), hepatitis B, hepatitis C * An average alcohol intake of more than 14 units per week * A known permanent or unexplained elevation of serum transaminases \> 1.5 times the upper limit of normal * A positive screen for drugs of abuse * Acute infection requiring treatment within 4 weeks prior to screening * Diagnosed or treated malignancy within the past 5 years